Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690763 | 1.00 | CTSL (0.45) | CTSLCTSBCAPN1 | |
| SCHEMBL28732875 | 1.00 | CTSL (0.45) | CTSLCTSBCAPN1 | |
| Hydrochloric Acid SCHEMBL29063300 | 0.99 | CTSL (0.44) | CTSLCTSBCAPN1 | |
| Hydrochloric Acid SCHEMBL29609436 | 0.99 | CTSL (0.44) | CTSLCTSBCAPN1 | |
| Hydrochloric Acid SCHEMBL29063299 | 0.99 | CTSL (0.44) | CTSLCTSBCAPN1 | |
| SCHEMBL19605950 | 0.93 | CTSB (0.43) | CTSLCTSB | |
| SCHEMBL24828173 | 0.89 | CTSL (0.41) | CTSLCTSBCAPN1 | |
| SCHEMBL23824248 | 0.88 | CTSL (0.43) | CTSLCTSBCAPN1 | |
| SCHEMBL24109107 | 0.88 | CTSL (0.42) | CTSLCTSBCAPN1 | |
| SCHEMBL24486589 | 0.88 | CTSL (0.42) | CTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACEA Therapeutics, Inc. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-08-15 | — | — | US | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021250648-A1 | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2017197377-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20140243341-A1 | BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | CTSL 280/4885CTSB 583/4885CAPN1 404/4885 |
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885CAPN1 158/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSL 3/4885CTSB 14/4885CAPN1 169/4885 |
| US-20140243341-A1 | BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES | GTF3C3, TMPRSS15, PRSS3 | CTSL 27/4885CTSB 139/4885CAPN1 54/4885 |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | CTSL 280/4885CTSB 583/4885CAPN1 404/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885CAPN1 176/4885 |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 24/4885CAPN1 150/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885CAPN1 176/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885CAPN1 176/4885 |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | CTSL 88/4885CTSB 764/4885CAPN1 242/4885 |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CTSL 3/4885CTSB 28/4885CAPN1 138/4885 |
| US-11987554-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885CAPN1 158/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | CTSL 280/4885CTSB 583/4885CAPN1 404/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885CTSB 32/4885CAPN1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.